MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

NCT05448001 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 329

Last updated 2024-08-26

No results posted yet for this study

Summary

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer

Conditions

  • Gastric Ulcer

Interventions

DRUG

JP-1366 20mg

JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal

DRUG

Lansoprazole 30mg

JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal

Sponsors & Collaborators

  • Onconic Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2024-07-10
Completion
2024-07-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05448001 on ClinicalTrials.gov